Wellington Management Group LLP Sells 8,417,221 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Wellington Management Group LLP lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 77.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,506,138 shares of the life sciences company's stock after selling 8,417,221 shares during the quarter. Wellington Management Group LLP owned about 3.25% of Integra LifeSciences worth $56,839,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norges Bank bought a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $8,967,000. Access Investment Management LLC bought a new position in Integra LifeSciences in the 4th quarter valued at $4,416,000. Charles Schwab Investment Management Inc. boosted its holdings in Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after purchasing an additional 125,620 shares during the period. JPMorgan Chase & Co. grew its position in shares of Integra LifeSciences by 130.5% during the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock valued at $4,529,000 after purchasing an additional 113,061 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Integra LifeSciences by 824.5% in the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock worth $2,031,000 after purchasing an additional 99,685 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Separately, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Integra LifeSciences Price Performance

Shares of NASDAQ IART traded up $0.01 during mid-day trading on Monday, reaching $19.58. 770,282 shares of the company were exchanged, compared to its average volume of 1,045,530. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $34.79. The company's 50 day moving average price is $23.23 and its 200 day moving average price is $22.35. The stock has a market capitalization of $1.51 billion, a PE ratio of -217.53, a PEG ratio of 0.73 and a beta of 1.24. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter in the previous year, the company posted $0.89 earnings per share. The company's revenue was up 11.5% compared to the same quarter last year. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.